D-PLEX 100 NDA under FDA review for colorectal SSI prevention; approval decision tests whether Phase 3 efficacy translates to first-in-class commercial launch

Bull

A positive FDA approval decision would validate the SHIELD II Phase 3 data showing a 60% relative risk reduction in SSIs (p=0.0013) and grant D-PLEX 100 first-in-class status in colorectal SSI prevention, unlocking commercial launch with a U.S. partner already in late-stage negotiations; this would transform PolyPid from a development-stage company into a commercial-stage entity in a large, underserved surgical complication market.

Bear

FDA could issue a Complete Response Letter citing manufacturing or CMC deficiencies, request additional clinical data, or question the adequacy of the single pivotal trial, any of which would delay approval by 12 or more months and strain the company's runway given its small cash position; a rejection on clinical grounds — particularly around endpoint definitions or the patient population's representativeness — would be the most thesis-destructive outcome.